Page last updated: 2024-09-22

6-nitroindazole

Cross-References

ID SourceID
PubMed CID24239
CHEMBL ID54277
SCHEMBL ID271522
SCHEMBL ID15066491
MeSH IDM0272467

Synonyms (63)

Synonym
AC-650
MLS001148387
smr000059016
MLS000069593 ,
6-nitroisoindazole
nsc-35066
nsc35066
7597-18-4
1h-indazole, 6-nitro-
6-nitro-1h-indazole
6-nitroindazole
einecs 231-500-9
brn 0007812
nsc 35066
nsc 56816
ccris 3263
nsc56816
nsc-56816
NCGC00024743-01
tocris-0710
inchi=1/c7h5n3o2/c11-10(12)6-2-1-5-4-8-9-7(5)3-6/h1-4h,(h,8,9
6NI ,
AQ-776/42801160
6-nitroindazole, 97%
DB03100
N-2920
CHEMBL54277 ,
N0399
bdbm50284964
AKOS000121370
A838566
A9641
STK772159
6-nitro-2h-indazole
65750-02-9
HMS2233A08
5-23-06-00183 (beilstein handbook reference)
6-nitro-indazole
FT-0621274
AM20041127
PB17036
HMS3371G13
SCHEMBL271522
6-nitro-indazol
CS-M3172
BS-3879
SCHEMBL15066491
OPERA_ID_909
F0001-1920
SR-01000597626-1
sr-01000597626
mfcd00005695
SY003000
F18039
6-nitroindzole
2h-indazole,6-nitro-
BCP27055
EN300-16639
BB 0304023
Q27456476
DTXSID40884407
PD059858
Z56347246

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency15.84890.003245.467312,589.2998AID2517
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
IDH1Homo sapiens (human)Potency0.41090.005210.865235.4813AID686970
gemininHomo sapiens (human)Potency14.81120.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.84890.00419.962528.1838AID2675
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency17.78281.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)32.00000.00071.979812.5000AID449904
Nitric oxide synthase, brainHomo sapiens (human)IC50 (µMol)32.00000.03502.711910.0000AID449904
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
response to hypoxiaNitric oxide synthase, brainHomo sapiens (human)
regulation of sodium ion transportNitric oxide synthase, brainHomo sapiens (human)
arginine catabolic processNitric oxide synthase, brainHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, brainHomo sapiens (human)
striated muscle contractionNitric oxide synthase, brainHomo sapiens (human)
myoblast fusionNitric oxide synthase, brainHomo sapiens (human)
response to heatNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transport into cytosolNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingNitric oxide synthase, brainHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, brainHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNitric oxide synthase, brainHomo sapiens (human)
multicellular organismal response to stressNitric oxide synthase, brainHomo sapiens (human)
xenobiotic catabolic processNitric oxide synthase, brainHomo sapiens (human)
vasodilationNitric oxide synthase, brainHomo sapiens (human)
negative regulation of potassium ion transportNitric oxide synthase, brainHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, brainHomo sapiens (human)
positive regulation of DNA-templated transcriptionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINitric oxide synthase, brainHomo sapiens (human)
negative regulation of hydrolase activityNitric oxide synthase, brainHomo sapiens (human)
negative regulation of serotonin uptakeNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transportNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contractionNitric oxide synthase, brainHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityNitric oxide synthase, brainHomo sapiens (human)
cellular response to growth factor stimulusNitric oxide synthase, brainHomo sapiens (human)
positive regulation of the force of heart contractionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayNitric oxide synthase, brainHomo sapiens (human)
positive regulation of sodium ion transmembrane transportNitric oxide synthase, brainHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelNitric oxide synthase, brainHomo sapiens (human)
positive regulation of membrane repolarization during ventricular cardiac muscle cell action potentialNitric oxide synthase, brainHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, brainHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, brainHomo sapiens (human)
response to hormoneNitric oxide synthase, brainHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, brainHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, brainHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
nitric-oxide synthase activityNitric oxide synthase, brainHomo sapiens (human)
calcium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
protein bindingNitric oxide synthase, brainHomo sapiens (human)
calmodulin bindingNitric oxide synthase, brainHomo sapiens (human)
FMN bindingNitric oxide synthase, brainHomo sapiens (human)
sodium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
heme bindingNitric oxide synthase, brainHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, brainHomo sapiens (human)
arginine bindingNitric oxide synthase, brainHomo sapiens (human)
transmembrane transporter bindingNitric oxide synthase, brainHomo sapiens (human)
cadmium ion bindingNitric oxide synthase, brainHomo sapiens (human)
calcium-dependent protein bindingNitric oxide synthase, brainHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, brainHomo sapiens (human)
NADP bindingNitric oxide synthase, brainHomo sapiens (human)
scaffold protein bindingNitric oxide synthase, brainHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor inner segmentNitric oxide synthase, brainHomo sapiens (human)
nucleoplasmNitric oxide synthase, brainHomo sapiens (human)
cytoplasmNitric oxide synthase, brainHomo sapiens (human)
mitochondrionNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
cytoskeletonNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
sarcoplasmic reticulumNitric oxide synthase, brainHomo sapiens (human)
sarcolemmaNitric oxide synthase, brainHomo sapiens (human)
dendritic spineNitric oxide synthase, brainHomo sapiens (human)
membrane raftNitric oxide synthase, brainHomo sapiens (human)
synapseNitric oxide synthase, brainHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, brainHomo sapiens (human)
cell peripheryNitric oxide synthase, brainHomo sapiens (human)
protein-containing complexNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
postsynaptic densityNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
nucleusNitric oxide synthase, brainHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID449904Inhibition of NOS12009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation.
AID1129169Inhibition of Escherichia coli DNA polymerase 3 beta assessed as inhibition of 5-carboxyfluorescein-QLDLF binding at <1 mM by fluorescence polarization-based competition assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Discovery of lead compounds targeting the bacterial sliding clamp using a fragment-based approach.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (14.29)18.2507
2000's3 (21.43)29.6817
2010's5 (35.71)24.3611
2020's4 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]